Review





Similar Products

vegfc  (R&D Systems)
94
R&D Systems vegfc
Vegfc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/Recombinant+Human+VEGF-C+(Cys156Ser)+Protein/pm41944190-231-16-17
Average 94 stars, based on 1 article reviews
vegfc - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
purified recombinant rat vegf c protein 152s  (Biosynth Carbosynth)
94
Biosynth Carbosynth purified recombinant rat vegf c protein 152s
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Purified Recombinant Rat Vegf C Protein 152s, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/VEGF+C+protein/pmc13012992-75-20-26
Average 94 stars, based on 1 article reviews
purified recombinant rat vegf c protein 152s - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
recombinant human vegf c c156s  (R&D Systems)
95
R&D Systems recombinant human vegf c c156s
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Recombinant Human Vegf C C156s, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/Recombinant+Human+VEGF-C+Protein/pm41797259-55-0-4
Average 95 stars, based on 1 article reviews
recombinant human vegf c c156s - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
recombinant vegf c protein  (Novoprotein)
86
Novoprotein recombinant vegf c protein
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Recombinant Vegf C Protein, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/human+mouse+recombinant+vegfa/10__3390_slash_cimb48030259-194-0-14
Average 86 stars, based on 1 article reviews
recombinant vegf c protein - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
recombinant vegf c cys156ser protein  (R&D Systems)
94
R&D Systems recombinant vegf c cys156ser protein
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Recombinant Vegf C Cys156ser Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/Recombinant+Human+VEGF-C+(Cys156Ser)+Protein/bio_rxiv__64898__2026__01__28__702461-134-12-22
Average 94 stars, based on 1 article reviews
recombinant vegf c cys156ser protein - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
human vegf standard  (R&D Systems)
95
R&D Systems human vegf standard
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Human Vegf Standard, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/Recombinant+Human+VEGF-C+Protein/pmc13058789-188-20-23
Average 95 stars, based on 1 article reviews
human vegf standard - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
recombinant human vegfc  (R&D Systems)
95
R&D Systems recombinant human vegfc
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Recombinant Human Vegfc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/Recombinant+Human+VEGF-C+Protein/pm41427784-291-35-40
Average 95 stars, based on 1 article reviews
recombinant human vegfc - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
2179 vc 025  (R&D Systems)
95
R&D Systems 2179 vc 025
VEGF-C <t>152s</t> treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
2179 Vc 025, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+proteins+vegf+c/Recombinant+Human+VEGF-C+Protein/pm41427784-291-39-40
Average 95 stars, based on 1 article reviews
2179 vc 025 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

Image Search Results


VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Journal: Frontiers in Cardiovascular Medicine

Article Title: Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice

doi: 10.3389/fcvm.2026.1699372

Figure Lengend Snippet: VEGF-C 152s treatment prior to ovariectomy limited the negative effects of subsequent E2 supplementation on lymphatic function and plaque burden in ldlr −/− mice. (A) Experimental design. 7 weeks old Ldlr −/− female mice received IP injections of VEGF-C 152s (e.g., VEGF-C) or vehicle. At 11 weeks, mice underwent either bilateral ovariectomy (OVX) or sham surgery, and switched on a high-fat diet (HFD). Estrogen (E2) supplementation began one week later. Lymphatic function was assessed in mice immediately prior to sacrifice at 20.5 weeks, after which organs were harvested. Green, orange and pink dashed lines represent VEGF-C 152s injections, HFD, and E2 implant durations, respectively. (B) Total body weight at the time of sacrifice and (C) over 21 weeks were reported. (D) Weight of visceral adipose tissue and (E) weight of the uterus, each expressed as percentage of total body weight. (F) Plasma total cholesterol and, (G) lipoprotein profile were assessed. (H) Contraction frequency of the popliteal collecting lymphatic vessels was measured by intravital microscopy. (I) Representative images of en face oil-red-O staining of the aorta and quantification of atherosclerotic plaque burden, expressed as percentage of total aortic area. Data points represent individual animals. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. HFD, high-fat diet; OVX, ovariectomy; VEGF-C, vascular endothelial growth factor C; CM, chylomicron; VLDL, very-low density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Article Snippet: Mice received intraperitoneal (IP) injections of VEGF-C (152s) at a dose of 50 ng per 25 g of body weight [purified recombinant rat VEGF-C protein (152s), Fitzgerald, catalog no. 30R-AV006-22] or vehicle control (phosphate-buffered saline, PBS), administered three times per week for four consecutive weeks.

Techniques: Clinical Proteomics, Intravital Microscopy, Staining